1. Department of Otolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. 2. Preeminent Medical Photonics Education and Research Center Institute for NanoSuit Research, Hamamatsu University School of Medicine, Hamamatsu, Japan.
✉ Corresponding author: Kiyoshi Misawa, Department of Otolaryngology/Head and Neck Surgery, 1-20-1 Handayama, Hamamatsu University School of Medicine, Shizuoka, 431-3192, Japan; Phone: 81-53-435-2252, Fax: 81-53-435-2253; E-mail: kiyoshimac.jp.More
Citation:
Yamada S, Misawa K, Mima M, Imai A, Mochizuki D, Yamada T, Shinmura D, Kita J, Ishikawa R, Yamaguchi Y, Misawa Y, Kawasaki H, Mineta H. Telomere shortening in head and neck cancer: association between DNA demethylation and survival. J Cancer 2021; 12(8):2165-2172. doi:10.7150/jca.54760. https://www.jcancer.org/v12p2165.htm
A growing body of evidence indicates that telomere dysfunction is a biological marker of progression in several types of cancer. However, the association between head and neck squamous cell carcinoma (HNSCC) and telomere length (TL) remains unknown. We measured the absolute TL levels in a well-characterised dataset of 211 tumoral vs normal tissues obtained from the same patients by quantitative polymerase chain reaction assay. Normalised TL levels were significantly lower in tumour samples than in normal tissue (P < 0.001) and there was a positive correlation between tumour tissue and normal mucosal tissue (R2 = 0.176, P < 0.001). We were able to distinguish two classes, one with a tumour/normal TL ratio ≤ 0.3 (38.4%), which showed clear telomere erosion, and the other with a tumour/normal TL ratio > 0.3 (61.6%), in which the TL was slightly shorter or longer than that in normal tissue. Notably, the tumour/normal TL ratio was correlated with the likelihood of disease recurrence (P = 0.002), the 5-hydroxymethylcytosine level (P = 0.043), and expression of the ten-eleven translocation (TET) gene (P = 0.043). Our findings show that TL shortening and subsequent low levels of 5-hydroxymethylcytosine and TET expression may contribute to development of HNSCC.
Yamada, S., Misawa, K., Mima, M., Imai, A., Mochizuki, D., Yamada, T., Shinmura, D., Kita, J., Ishikawa, R., Yamaguchi, Y., Misawa, Y., Kawasaki, H., Mineta, H. (2021). Telomere shortening in head and neck cancer: association between DNA demethylation and survival. Journal of Cancer, 12(8), 2165-2172. https://doi.org/10.7150/jca.54760.
ACS
Yamada, S.; Misawa, K.; Mima, M.; Imai, A.; Mochizuki, D.; Yamada, T.; Shinmura, D.; Kita, J.; Ishikawa, R.; Yamaguchi, Y.; Misawa, Y.; Kawasaki, H.; Mineta, H. Telomere shortening in head and neck cancer: association between DNA demethylation and survival. J. Cancer 2021, 12 (8), 2165-2172. DOI: 10.7150/jca.54760.
NLM
Yamada S, Misawa K, Mima M, Imai A, Mochizuki D, Yamada T, Shinmura D, Kita J, Ishikawa R, Yamaguchi Y, Misawa Y, Kawasaki H, Mineta H. Telomere shortening in head and neck cancer: association between DNA demethylation and survival. J Cancer 2021; 12(8):2165-2172. doi:10.7150/jca.54760. https://www.jcancer.org/v12p2165.htm
CSE
Yamada S, Misawa K, Mima M, Imai A, Mochizuki D, Yamada T, Shinmura D, Kita J, Ishikawa R, Yamaguchi Y, Misawa Y, Kawasaki H, Mineta H. 2021. Telomere shortening in head and neck cancer: association between DNA demethylation and survival. J Cancer. 12(8):2165-2172.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Global reach, higher impact
